Pluristem Therapeutics, a company that develops placenta-based cell therapy products, announced that its licensing partner United Therapeutics is advancing the Phase I study of Pluristem's PLacental eXpanded (PLX-PAD) cells in patients with pulmonary arterial hypertension (PAH).
PLacental eXpanded (PLX) cells are developed by Pluristem to serve as protein delivery platforms that release a mix of proteins for ischemia or inflammation. The treatment technology is also being used to investigate tendon-healing treatments in a preclinical model of tendon injury. The company presented results at the American Academy of Orthopedic Surgeons’ (AAOS) Annual Meeting last March in New Orleans.